Boundless Competitors
| BOLD Stock | USD 1.15 0.06 5.50% |
Boundless Bio vs TAO Synergies Correlation
Average diversification
The correlation between Boundless Bio Common and TAOX is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Boundless Bio Common and TAOX in the same portfolio, assuming nothing else is changed.
Moving against Boundless Stock
| 0.51 | ALT | Altimmune | PairCorr |
| 0.33 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.33 | DSGN | Design Therapeutics | PairCorr |
Boundless Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Boundless Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Boundless and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Boundless Bio Common does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Boundless Stock performing well and Boundless Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Boundless Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| QTTB | 4.88 | 0.88 | 0.15 | (2.43) | 4.68 | 7.51 | 85.16 | |||
| NXTC | 4.38 | (0.03) | (0.01) | 0.01 | 5.45 | 9.04 | 43.11 | |||
| PSTV | 4.82 | (1.10) | 0.00 | (0.41) | 0.00 | 8.93 | 48.30 | |||
| INTS | 5.00 | (1.00) | 0.00 | (0.31) | 0.00 | 10.87 | 51.11 | |||
| ITRM | 4.67 | (1.16) | 0.00 | (0.43) | 0.00 | 9.38 | 28.58 | |||
| ANTX | 2.55 | (0.21) | 0.00 | (0.13) | 0.00 | 4.55 | 32.31 | |||
| PLUR | 3.81 | (0.18) | 0.00 | (0.07) | 0.00 | 9.30 | 31.25 | |||
| RLYB | 3.02 | (0.28) | 0.00 | (0.14) | 0.00 | 6.94 | 17.61 | |||
| SONN | 10.16 | (0.25) | 0.00 | (0.90) | 0.00 | 19.48 | 69.59 | |||
| TAOX | 5.77 | (0.78) | 0.00 | (0.57) | 0.00 | 12.66 | 36.28 |
Cross Equities Net Income Analysis
Compare Boundless Bio Common and related stocks such as Q32 Bio, NextCure, and Plus Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTTB | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (30 M) | (55.6 M) | (103.9 M) | (128.7 M) | (95.8 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (33.2 M) | (69.4 M) | (69.4 M) | (62.7 M) | (55.7 M) | (50.1 M) | (52.6 M) |
| PSTV | (2.1 M) | (32.5 M) | (32.3 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (10.9 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (11.7 M) | (12.3 M) |
| INTS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| PLUR | (77.9 K) | (14.8 M) | (21.2 M) | (26.9 M) | (24.7 M) | (23.2 M) | (27.8 M) | (26.1 M) | (35.3 M) | (29.2 M) | (49.9 M) | (41.2 M) | (28.3 M) | (20.9 M) | (22.6 M) | (20.3 M) | (21.3 M) |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (5.6 M) | (6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
Boundless Bio Common and related stocks such as Q32 Bio, NextCure, and Plus Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Boundless Bio Common financial statement analysis. It represents the amount of money remaining after all of Boundless Bio Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Boundless Bio Competitive Analysis
The better you understand Boundless Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Boundless Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Boundless Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Boundless Bio Competition Performance Charts
Five steps to successful analysis of Boundless Bio Competition
Boundless Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Boundless Bio Common in relation to its competition. Boundless Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Boundless Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Boundless Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Boundless Bio Common, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Boundless Bio position
In addition to having Boundless Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Allocation ETFs Thematic Idea Now
Asset Allocation ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 189 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Boundless Bio Correlation with its peers. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.